Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

BOSTON, Feb. 07, 2024 -- Rhythm Pharmaceuticals, Inc. , a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare...

Related Keywords

Canada ,United States ,Boston ,Massachusetts ,Italy ,United Kingdom ,Italian ,Adam Daley ,David Connolly ,Yann Mazabraud ,Drug Administration ,Nasdaq ,Berry Company Public Relations ,Gazzetta Ufficiale ,Corporate Communications ,Rhythm Pharmaceuticals Inc ,Head Of International At Rhythm ,Rhythm Pharmaceuticals ,European Union ,Italian Medicine Agency ,Medicines Healthcare Products Regulatory Agency ,European Commission ,Exchange Commission ,Executive Vice President ,Healthcare Products Regulatory Agency ,Prescribing Information ,Important Safety ,Private Securities Litigation Reform Act ,Quarterly Report ,Investor Relations ,Markets ,